tbuckley/cabot-search huggingface dataset:
John Norman Agate Henry Dundas Cockburn Edgar Colin Colin-Jones Wilfrid Henry Russell Cook Kenneth Hazell Frank Marr Milne James Joseph Murray John Richard Rose Derek Seymour-Jones John Emerson ("Jack") Simpson Alice Eleanora Townsley Catrin Williams
Authors: B. Moore-Smith, A. Fraser, D G Colin-Jones, M. Cook, V. M Hazell, J. S G Blair, M. Murray, M. Rose, J. Billinghurst, H. Dinwoodie, N A. Green, Z Hammad
Journal: BMJ (1999)

# John Norman Agate {#article-title-2}

Pioneer in British geriatric medicine ( b 1919; q Cambridge/London 1942; MD, FRCP; CBE), d 31 October 1998. John decided to enter the fledgling specialty of geriatric medicine in 1953 after four years with the Medical Research Council's industrial unit and a short service commission with the Royal Air Force. He began as a consultant in Bradford, serving 730 beds, then in 1958 he moved to Ipswich with 520. In Ipswich and east Suffolk he was a driving force in the move from essentially long stay services to the acute medicine of older people supported by effective rehabilitation enabling them to return home safely. To this end he planned, obtained funding for, and opened 50 acute beds in 1967 followed by 50 rehabilitation beds 10 years later, having already in the early and mid-1960s overseen the major refurbishment of four peripheral longer stay hospitals. As a clinician he put history taking and physical examination far ahead of laboratory results, as many junior colleagues learnt to their cost. Plagued by back pain, John conducted ward rounds sitting on a shooting stick and kneeling to examine. He set high standards, fought vigorously for his beliefs, and, though possessed of a “short fuse,” he was essentially a kind man. In 1963 he published The Practice of Geriatrics , which became the definitive textbook of the time. An influential office holder of the British Geriatric Society, John also sat on several national committees, and his services to geriatric medicine were marked by award of the CBE in 1978. Outside medicine his interests included music, photography, pottery, writing, and cars. He leaves a wife, Hester; a son and a daughter; and a grandson.

# Henry Dundas Cockburn {#article-title-3}

Former medical superintendent St Mary's Hospital, London ( b Ealing 1913; q St Mary's 1939; MC), d 4 December 1998. He joined the Royal …
Long-term investigation of new-borns of HBsAg positive mothersvaccinated against hepatitis B
Authors: L. Rožnovský, I. Lochman, L. Lukacova Sulakova, Alena Zjevíková, A. Šuláková, Irena Orságová, L. Pliskova, A. Kloudova, J. Chovančík
Journal: Clinical Microbiology and Infection (2002)
Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice
Authors: Grégory Franck, Thomas Mawson, Grasiele Sausen, Manuel Salinas, Gustavo Santos Masson, Andrew Cole, Marina Beltrami-Moreira, Yiannis Chatzizisis, Thibault Quillard, Yevgenia Tesmenitsky, Eugenia Shvartz, Galina K. Sukhova, Filip K. Swirski, Matthias Nahrendorf, Elena Aikawa, Kevin J. Croce, Peter Libby
Journal: Circulation Research (2017)

Superficial erosion currently causes up to a third of acute coronary syndromes; yet, we lack understanding of its mechanisms. Thrombi because of superficial intimal erosion characteristically complicate matrix-rich atheromata in regions of flow perturbation.This study tested in vivo the involvement of disturbed flow and of neutrophils, hyaluronan, and Toll-like receptor 2 ligation in superficial intimal injury, a process implicated in superficial erosion.In mouse carotid arteries with established intimal lesions tailored to resemble the substrate of human eroded plaques, acute flow perturbation promoted downstream endothelial cell activation, neutrophil accumulation, endothelial cell death and desquamation, and mural thrombosis. Neutrophil loss-of-function limited these findings. Toll-like receptor 2 agonism activated luminal endothelial cells, and deficiency of this innate immune receptor decreased intimal neutrophil adherence in regions of local flow disturbance, reducing endothelial cell injury and local thrombosis (P<0.05).These results implicate flow disturbance, neutrophils, and Toll-like receptor 2 signaling as mechanisms that contribute to superficial erosion, a cause of acute coronary syndrome of likely growing importance in the statin era.
The clinical predictor of antitumor efficacy of cetuximab retreatment in patients with metastatic colorectal cancer who had a clinical benefit in response to prior cetuximab based regimen
Authors: Hiroaki Tanioka, Motoi Asano, Ryousuke Yoshida, Naohisa Waki, Masahiro Ishizaki, Kazuki Yamashita, Yoshiko Mori, Takeshi Nagasaka
Journal: Annals of Oncology (2017)
Regulation of vascular smooth muscle cell calcification by syndecan-4/FGF-2/PKCα signalling and cross-talk with TGFβ
Authors: Samantha J. Borland, Thomas G. Morris, Shona C. Borland, Mark R. Morgan, Sheila E. Francis, Catherine L.R. Merry, Ann E. Canfield
Journal: Cardiovascular Research (2017)

Vascular calcification is a major cause of morbidity and mortality. Fibroblast growth factor-2 (FGF-2) plays an instructive role in osteogenesis and bone development, but its role in vascular calcification was unknown. Therefore, we investigated the involvement of FGF-2 in vascular calcification and determined the mechanism by which it regulates this process. We demonstrate that FGF-2 expression is increased in vascular smooth muscle cells (VSMCs) induced to deposit a mineralized matrix by incubation with β-glycerophosphate. FGF-2 is also localized to sites of calcification within human atherosclerotic plaques. The expression of syndecan-4, a heparan sulfate proteoglycan which regulates FGF-2 signalling, is also increased in mineralizing VSMCs and co-localizes with FGF-2 in human calcified atherosclerotic plaques. Exogenous FGF-2 inhibits VSMC mineralization, and this inhibition is reduced when syndecan-4 expression is knocked-down using siRNA. Biochemical inhibition of FGFR signalling using a pan FGFR inhibitor (BGJ398) or knocking-down syndecan-4 expression in VSMCs using siRNA increases VSMC mineralization. These increases are prevented by inhibiting transforming growth factor-β (TGFβ) signalling with SB431542, suggesting cross-talk between FGF-2 and TGFβ signalling is crucial for the regulation of VSMC mineralization. Syndecan-4 can also regulate FGF-2 signalling directly via protein kinase Cα (PKCα) activation. Biochemical inhibition of PKCα activity using Gö6976, or siRNA-mediated suppression of PKCα expression increases VSMC mineralization; this increase is also prevented with SB431542. Finally, the ability of FGF-2 to inhibit VSMC mineralization is reduced when PKCα expression is knocked-down. This is the first demonstration that syndecan-4 promotes FGF-2 signalling, and in turn, suppresses VSMC mineralization by down-regulating TGFβ signalling. Our discoveries that FGF-2 and syndecan-4 expression is increased in mineralizing VSMCs and that PKCα regulates FGF-2 and TGFβ signalling in VSMCs suggests that the syndecan-4/FGF-2/TGFβ signalling axis could represent a new therapeutic target for vascular calcification.
Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study.
Authors: Fatih Kose, Ali Murat Sedef, Nuriye Özdemir, Meral Gunaldi, Yuksel Urun, Ali Ayberk Besen, Ahmet Taner Sumbul, Sema Sezgin Goksu, Ozlem Dogan, Huseyin Mertsoylu, Ali Murat Tatli, Dilek Erdem, Serkan Demirci, Seyda Gunduz, Mustafa Yildirim, Ozgur Ozyilkan, Huseyin Abali
Journal: Journal of Clinical Oncology (2015)

e15030 Background: There are two major histological types of gastric adenocarcinoma, intestinal and diffuse and intestinal type further classified as proximal(with obesity and Barrett esophagus) and distal(H. Pylori ). These subtypes have distinct morphological appearance, pathogenesis and different biological behavior. Backbone of chemotherapy consisted of 5-fluoracil and platinum (PF), addition of taxanes (PFtax)provide significantly better survival and higher response rate but come with higher chance of hematological toxicity.With this study, we aim to evaluate whether tumor localization has predictive role for addition of taxanes or not. Methods: Total number of 305 metastatic gastric adenocarcinoma patients were included. Results: Rates of male patients were 69,8 % (n = 213). Proximal, distal intestinal, and diffuse gastric cancer were founded in 68 (19,8%), 217(71%), and 28(9,2%) patients, respectively. PF(platin-5FU) and PFtax (platin-5-FU-taxane) were administered to 78(25,6%) and 227(74,4%) patients respectively. Median progression free survival (PFS) was 5.0 and 8months for PF and PFtax groups, respectively (p = 0.001). When we use tumor localization as strata in PFS survival curve, PFtax produce significantly higher PFS onlyin distal intestinal type gastric cancer compared to PF(p = 0.006). Median overall survival(OS) was 12 and 16 months for PF and PFtax groups, respectively (p > 0.05). When we use tumor localization as strata in OS survival curve, statistical analysis failed to show significant difference between tumor localizations. (p > 0.05). Conclusions: There is no standard first line chemotherapy protocol for HER-2 negative advanced metastatic gastric cancer in literature. With this study, we showed that addition of taxanes significantly increases PFS time only in distal intestinal type gastric cancer not in proximal and diffuse type gastric cancer patients. This result will assist decision making in advanced gastric cancer for choosing which patients will take taxanes as a part of the first line treatment.
Residency Training in Long-Acting Reversible Contraceptive Methods
Authors: Meghan Geary, Christine Prifti, Alexandra Bachorik
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
RECREATIONAL RUNNER' STRATEGIES TO COPE WITH INJURY AND ILLNESS DURING MARATHON RACE PREPARATIONS: CROSS-SECTIONAL STUDY IN SWEDEN
Authors: Håkan Gauffin, Bo Tillander, Örjan Dahlström, Henrik Nyman, Toomas Timpka
Journal: British Journal of Sports Medicine (2017)

Background Running is one of the most popular forms of physical exercise worldwide. It is therefore discomforting that pain and overuse injuries are common among recreational runners. The coping concept is used to denote conscious efforts to solve personal and interpersonal problems, and seeking to master, minimize or tolerate stress or conflict. Objective To explore coping strategies associated with injury and illness management in runners. Design Cross-sectional study based on an online survey. Setting Recreational runners preparing for a marathon race. Patients (or Participants) Swedish recreational marathon runners. Interventions (or Assessment of Risk Factors) Age, sex, and coping strategies as measured by the Brief Cope instrument. Main Outcome Measurements Episodes of injury or illness lasting at least three weeks during the past 12 months. Results The response rate was 38% (317/833 runners). One out of five runners reported a pre-race health problem, with overuse injuries with gradual onset being the most frequent problem and the knee the most common localisation. No statistical differences between injured and non-injured runners were observed for any feature of the Brief Cope instrument. Runners having rested from running due to illness reported higher scores for the adaptive coping strategy active coping (p=0.020). They also reported lower scores for emotional support (p=0.020) and higher scores for the maladaptive coping strategy behavioural disengagement (p=0.041) than runners not having rested for illness. Conclusions An association between active coping and rest due to illness was found among recreational marathon runners. Illness, usually having a sudden onset, seem to motivate marathon runners to rest more strongly than overuse injuries that normally have a gradual onset. The results indicate that health problems with gradual onset call for different approaches for behavioural interventions and prevention than those with sudden onset. Coping strategies among recreational runners warrant further research based on longitudinal study designs.
Physical fitness training for stroke survivors (PEDro synthesis)
Authors: Tiê Parma Yamato, Leanne Hassett
Journal: British Journal of Sports Medicine (2017)

Saunders DH, Sanderson M, Hayes S, et al . Physical fitness training for stroke patients. Cochrane Database of Systematic Reviews 2016; Issue 3: CD003316.

Loss of cardiorespiratory fitness is a common secondary impairment frequently observed in people after stroke, resulting from a combination of primary impairments such as muscle weakness and decreased physical activity.1 Low fitness is likely to restrict return to life role participation.2 Physical fitness training programmes are often prescribed to address loss of fitness and involve either cardiorespiratory training, resistance training or mixed training which combines both.

The study aimed to determine the effectiveness of physical fitness training in reducing death, dependence and disability after stroke. The secondary aims included evaluating the effects of physical fitness training on mobility, physical fitness, quality of life, mood and cognitive function.

Eleven electronic databases and four trial registry platforms were searched up to February 2015, and included randomised controlled trials that examined the effects of cardiorespiratory, resistance or mixed training. The review included adult stroke survivors who were suitable for fitness training.

The intervention groups included cardiorespiratory training (eg, treadmill walking, cycle …
AN IMPORTANT FACTOR IN THE SUCCESSFUL TREATMENT OF MALARIA
Authors: De Buys
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Authors: Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang, Xiaoquan Zhang, Hui Wang, Helgi van de Velde, Paul G. Richardson, Philippe Moreau
Journal: Journal of Hematology & Oncology (2017)

The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies. Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage, and prior proteasome inhibitor exposure. The primary endpoint was progression-free survival (PFS). In total, 115 Chinese patients were randomized (57 ixazomib-Rd, 58 placebo-Rd). At the preplanned final analysis for PFS, after median PFS follow-up of 7.4 and 6.9 months, respectively, PFS was improved with ixazomib-Rd versus placebo-Rd (median 6.7 vs 4.0 months; HR 0.598; p = 0.035). At the preplanned final analysis of overall survival (OS), after median follow-up of 20.2 and 19.1 months, respectively, OS was improved with ixazomib-Rd versus placebo-Rd (median 25.8 vs 15.8 months; HR 0.419; p = 0.001). On the ixazomib-Rd and placebo-Rd arms, respectively, 38 (67%) and 43 (74%) patients reported grade ≥3 adverse events (AEs), 19 (33%) and 18 (31%) reported serious AEs, and 4 (7%) and 5 (9%) died on-study. The most frequent grade 3/4 AEs were thrombocytopenia (18%/7% vs 14%/5%), neutropenia (19%/5% vs 19%/2%), and anemia (12%/0 vs 26%/2%). This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-Rd, with limited additional toxicity, in patients with RRMM. ClinicalTrials.gov, NCT01564537
The implementation of a multidisciplinary heredofamilial cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital.
Authors: Miriam Lobo de Mena, Sara Lopez-Tarruella, Soledad Luque Molina, Santiago Lizarraga, Patricia Rincon, Angel Hernandez, Elsa Mendizabal, Oscar Bueno, Maria Cebollero, Sara Perez Ramirez, Yolanda Jerez, Isabel Palomero, Ricardo Gonzalez del Val, Iria Gallego, Isabel Echavarria Diaz Guardamino, Ana Calin, Jose Blanco, Carmen Flores Sanchez, Miguel Martin, Ivan Marquez Rodas
Journal: Journal of Clinical Oncology (2016)

e13031 Background: The identification of patients with Breast Cancer (BC) and genetic risk has proved a positive impact in reducing the mortality for BC and the prevention of second tumors. In 2010, we implemented a multidisciplinary Heredofamilial Cancer Unit (HFCU), systematizing the management of risk patients. We analyze if the HFCU could improve the rates of referrals and preventive management of patients with BC and genetic risk in our Institution. Methods: Retrospective study comparing family history record (FHR), referral of patients with high risk to genetic counseling (GC), detection of BRCA 1/2 mutations and management of BC patients diagnosed before (July 2007-June 2010, first period) and after the HFCU creation (July 2010-June 2013, second period) and treated in our university hospital Results: 893 patients (99.1% women) in the first period and 902 (99% women) in the second period met inclusion criteria. 142 patients (15.9%) vs 70 (7.8%) were not analyzable because a lack of complete information to establish the genetic risk (p < 0.05). Among evaluable patients, 194 (25.8%) vs 225 (27%) had any risk criteria (p NS). FHR, referral rate and preventive surgeries in BRCA mutation carriers significantly increased in the second period (table). Additionally, 56 risk patients diagnosed during the first period and not referred to GC were referred to the HFCU, detecting 9 additional BRCA mutations Conclusions: The creation of a multidisciplinary HFCU significantly increased the rates of FHR, referrals, and preventive surgeries of BC patients with genetic risk BEFORE HFCU (%) AFTER HFCU (%) FHR 825/893 (92.4) 882/902 (97.8)* Patients at risk referred to GC 51/194 (26.3) 116/225 (51.6)* BRCA 1/2 mutations detected 8/43 (18.6) 17/114 (14.9) Prophylactic surgeries in BRCA+ 2/8 (25) 15/17 (88.2)* *p < 0.05
Abstract P301: Investigation of the Mechanism of the Cardioprotective Effects of Flavonols in Langendorff Perfused Rat Hearts
Authors: Owen L Woodman, Cheng X Qin, Spencer J Williams
Journal: Circulation Research (2011)

We investigated the mechanism(s) of flavonol-induced cardioprotection using a flavonol which inhibits calcium utilization and has antioxidant activity 3’,4’-dihydroxylflavonol, a flavonol which only affects calcium activity 4’-OH-3’-OCH3 flavonol and a water-soluble flavonol with selective antioxidant activity DiOHF-6-succinamic acid in rat isolated hearts. Hearts were perfused with physiological solution using a Langendorff apparatus and subjected to global, no-flow 20-min ischaemia followed by 30-min reperfusion. Hearts (n = 6–8 per group) were randomly treated with vehicle (0.05% DMSO), DiOHF, 4’-OH-3’-OCH3 flavonol or DiOHF-6-succinamic acid (all 10 µM). Flavonols were included in the perfusate for 10 min before ischaemia and during the entire duration of reperfusion. In vehicle treated hearts, LV+dP/dt was significantly reduced at the end of reperfusion (60±8% decrease in LV+dP/dt) compared to the pre-ischaemic level. Furthermore, LDH release (895±121 U/L) was significantly elevated during reperfusion compared to shams (70±10 U/L) and total eNOS expression was significantly lower in vehicle-treated hearts. In comparison, DiOHF treatment significantly improved LV function upon reperfusion (35±6% reduction in LV+dP/dt), significantly decreased the level of LDH (265±66 U/L) and preserved total eNOS expression. Hearts treated with the antioxidant DiOHF-6-succinamic acid had a similar preservation of contractility, resulting in a 36±5% reduction in LV+dP/dt, and a significantly lower release of LDH (388±57 U/L) and preserved total eNOS expression. In contrast, hearts treated with 4’-OH-3’-OCH3 showed similar impairment of contractility to the vehicle group. DiOHF-6-succinamic acid also exerted cardioprotection when given only during reperfusion but not when administered only prior to ischaemia. This study demonstrated that flavonol-induced cardioprotection relies on the antioxidant activity and is mainly exerted during the reperfusion phase. The water-soluble DiOHF-6-succinamic acid with selective antioxidant activity may lead to the development of a new cardioprotective agent effective when applied at reperfusion and therefore appropriate for clinical use.